Fig. 5. KAT5 specifically promotes NLRP3 inflammasome activation in vitro.
a–h BMDMs from Kat5fl/fl (n = 3) or Kat5fl/flLyz2-Cre (n = 3) mice were treated with LPS (100 ng/mL, 3 h) along or with ATP (5 mM, 1 h), nigericin (10 μM, 1 h), MSU (200 μg/mL, 6 h), Flagellin transfection (2 μg/mL, 1 h) or poly (dA:dT) transfection (1 μg/mL, 16 h). a, b ELISA analysis of IL-1β and TNF-α in supernatants. c Release of LDH in supernatants. d Cell Lysates and supernatant were subjected to western blot analysis. e Immunoblot analysis of total and K24 acetylation level of NLRP3. f–h Immunoblot analysis of NLRP3 oligomerization and NLRP3, KAT5 expression by SDD-AGE, BN-PAGE and 2D-SDS-PAGE assay. Results are represented as mean ± SD and typical photographs are representative of three biological independent experiments with similar results. Statistical analyses were carried out via two-way ANOVA with the Bonferroni test for (a–c). Source data are provided as a Source Data file.